Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase III Pipeline Programs

Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Programs 5,427
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 5,427 phase iii pharmaceutical pipeline programs from ClinicalTrials.gov. Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Top sponsors

Pipeline programs

Page 23 of 114

  1. C2321008

    Pfizer Australia Pty Ltd

    METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER

    phase 3 small molecule active

    1 trial

  2. C2321014

    Pfizer Australia Pty Ltd

    METASTATIC CASTRATION RESISTANT PROSTATE CANCER

    phase 3 small molecule active

    1 trial

  3. C24-50

    The George Institute

    Semantic Variant Primary Progressive Aphasia, Alcohol Use Disorder, Organic amnesia syndrome, Narcolepsy, Alzheimer, Lewy Body Dementia

    phase 3 small molecule active

    1 trial

  4. C25003

    Takeda

    Advanced Classical Hodgkin Lymphoma

    phase 3 small molecule active

    1 trial

  5. C3391003

    Pfizer Australia Pty Ltd

    DUCHENNE MUSCULAR DYSTROPHY (DMD)

    phase 3 small molecule active

    1 trial

  6. C3441021

    Pfizer Australia Pty Ltd

    Metastatic Castration-resistant Prostate Cancer

    phase 3 small molecule active

    1 trial

  7. C3441052

    Pfizer Australia Pty Ltd

    Metastatic Castration-sensitive Prostate Cancer

    phase 3 small molecule active

    1 trial

  8. C3651021

    Pfizer Australia Pty Ltd

    Cancer cachexia

    phase 3 small molecule active

    1 trial

  9. C4221015

    Pfizer Australia Pty Ltd

    Colorectal cancer (BRAF V600E-mutant mCRC)

    phase 3 small molecule active

    1 trial

  10. C4221016

    Pfizer Australia Pty Ltd

    Metastatic or unresectable locally advanced BRAF V600E/K mutation positive melanoma

    phase 3 small molecule active

    1 trial

  11. C4391022

    Pfizer Australia Pty Ltd

    Hormone receptor-positive, her2-negative advanced/metastatic breast cancer

    phase 3 small molecule active

    1 trial

  12. C4391024

    Pfizer Australia Pty Ltd

    Advanced/Metastatic Breast Cancer

    phase 3 small molecule active

    1 trial

  13. C4551002

    Pfizer Australia Pty Ltd

    Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Cancer

    phase 3 small molecule active

    1 trial

  14. C4671026

    Pfizer Australia Pty Ltd

    SARS-CoV-2 Infection

    phase 3 small molecule active

    1 trial

  15. C4951002

    Pfizer Australia Pty Ltd

    Acute Migraine (with or without aura)

    phase 3 small molecule active

    1 trial

  16. C4951003

    Pfizer Australia Pty Ltd

    Acute Migraine (with or without aura)

    phase 3 small molecule active

    1 trial

  17. C4951009

    Pfizer Australia Pty Ltd

    Migraine (with or without aura)

    phase 3 small molecule active

    1 trial

  18. C4951013

    Pfizer Australia Pty Ltd

    Chronic Migraine

    phase 3 small molecule active

    1 trial

  19. C4951063

    Pfizer Australia Pty Ltd

    Menstrual Migraine

    phase 3 small molecule active

    1 trial

  20. C5041006

    Lacuna Pharma Pty Ltd

    Crohn's Disease

    phase 3 small molecule active

    1 trial

  21. C5091017

    Pfizer Australia Pty Ltd

    Covid-19 at high risk of progression to severe illness.

    phase 3 small molecule active

    1 trial

  22. C5091018

    Pfizer Australia Pty Ltd

    Coronavirus Disease 2019 (COVID-19)

    phase 3 small molecule active

    1 trial

  23. C5751003

    Pfizer Australia Pty Ltd

    non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  24. C6461001

    Pfizer Australia Pty Ltd

    LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER

    phase 3 small molecule active

    1 trial

  25. C6461003

    Pfizer Australia Pty Ltd

    Metastatic Colorectal Cancer

    phase 3 small molecule active

    1 trial

  26. C6461004

    Pfizer Australia Pty Ltd

    Extensive-Stage Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  27. CA017-078

    Bristol-Myers Squibb Australia Pty Ltd

    Bladder Cancer Muscle-Invasive Bladder Cancer

    phase 3 small molecule active

    1 trial

  28. CA0561060

    Celgene Europe Limited

    Myelodysplastic syndrome

    phase 3 small molecule active

    1 trial

  29. CA057-001

    Celgene Europe Limited

    Relapsed or Refractory Multiple Myeloma (RRMM)

    phase 3 small molecule active

    1 trial

  30. CA058-1019

    Celgene Europe Limited

    Relapsed and/or Refractory Multiple Myeloma

    phase 3 small molecule active

    1 trial

  31. CA071-1000

    Celgene Europe Limited

    Metastatic Castration-resistant Prostate Cancer (mCRPC)

    phase 3 small molecule active

    1 trial

  32. CA073-1003

    Celgene Europe Limited

    Relapsed/Refractory Follicular Lymphoma

    phase 3 small molecule active

    1 trial

  33. CA073-1020

    Celgene Europe Limited

    High-risk Large B-cell Lymphoma

    phase 3 small molecule active

    1 trial

  34. CA088-1007

    Celgene Europe Limited

    Relapsed or Refractory and Lenalidomide exposed Multiple Myeloma

    phase 3 small molecule active

    1 trial

  35. CA127-1030

    Bristol-Myers Squibb Australia Pty Ltd

    Non small cell lung cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  36. CA209-577

    Bristol-Myers Squibb Australia Pty Ltd

    Subjects with resected adenocarcinoma or squamous cell carcinoma esophageal or gastroesophageal junction cancer

    phase 3 small molecule active

    1 trial

  37. CA209-67T

    Bristol-Myers Squibb Australia Pty Ltd

    Metastatic Clear Cell Renal Cell Carcinoma

    phase 3 small molecule active

    1 trial

  38. CA209-8HW

    Bristol-Myers Squibb Australia Pty Ltd

    Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient Metastatic Colorectal Cancer (dMMR)

    phase 3 small molecule active

    1 trial

  39. CA209-8Y8

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced Renal Cell Carcinoma with Intermediate- or Poor-Risk Factors

    phase 3 small molecule active

    1 trial

  40. CA209-901

    Bristol-Myers Squibb Australia Pty Ltd

    Untreated Unresectable or Metastatic Urothelial Cancer

    phase 3 small molecule active

    1 trial

  41. CA209-9DW

    Bristol-Myers Squibb Australia Pty Ltd

    Hepatocellular Carcinoma, Hepatocellular Carcinoma, Hepatocellular Carcinoma, Hepatocellular Carcinoma

    phase 3 small molecule active

    1 trial

  42. CA209-9DX

    Bristol-Myers Squibb Australia Pty Ltd

    Hepatocellular Carcinoma

    phase 3 small molecule active

    1 trial

  43. CA209-9ER

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced or Metastatic Renal Cell Carcinoma

    phase 3 small molecule active

    1 trial

  44. CA209-9LA

    Bristol-Myers Squibb Australia Pty Ltd

    Stage IV Non-Small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  45. CA224-047

    Bristol-Myers Squibb Australia Pty Ltd

    Previously Untreated Metastatic or Unresectable Melanoma

    phase 3 small molecule active

    1 trial

  46. CA224-098

    Bristol-Myers Squibb Australia Pty Ltd

    Participants with completely resected Stage III or Stage IV melanoma

    phase 3 small molecule active

    1 trial

  47. CA224-123

    Bristol-Myers Squibb Australia Pty Ltd

    Metastatic Colorectal Cancer

    phase 3 small molecule active

    1 trial

  48. CA2241093

    Bristol-Myers Squibb Australia Pty Ltd

    Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many Phase III pipeline programs are in the directory?

5,427 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.